SCHEMBL14965104

SCHEMBL14965104

COC(=O)Cc1nc(Cl)c2c(-c3ccc(F)cc3)csc2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
LMNA P02545 2/20 0.48
TP53 P04637 1/20 0.44
HPGD P15428 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
SIRT5 Q9NXA8 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
PRNP P04156 1/20 0.41
CSNK2A2 P19784 1/20 0.41
CSNK2B P67870 1/20 0.41
CSNK2A1 P68400 1/20 0.41
TGM2 P21980 3/20 0.41
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16292993 0.96 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2LMNATP53HPGD
SCHEMBL3381310 0.90 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2LMNATP53HPGD
SCHEMBL14965186 0.80 LMNA (0.56) ALDH1A1SMN1; SMN2LMNATP53HPGD
SCHEMBL2369032 0.79 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2LMNAHPGDKDM4E
SCHEMBL2368929 0.74 LMNA (0.61) ALDH1A1SMN1; SMN2LMNATP53HPGD
SCHEMBL2368799 0.74 LMNA (0.64) ALDH1A1SMN1; SMN2LMNATP53HPGD
SCHEMBL2369471 0.72 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2LMNATP53HPGD
SCHEMBL2368271 0.72 PRKCZ (0.52) ALDH1A1SMN1; SMN2LMNATP53HPGD
SCHEMBL3385335 0.71 TNF (0.48) ALDH1A1SMN1; SMN2LMNAHPGDNPSR1
SCHEMBL3386420 0.70 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2LMNAHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160152634-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2016-06-02 US disclosed
EP-2780343-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS Xention Limited (GB) 2014-09-24 EP disclosed
WO-2013072694-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS XENTION LIMITED (GB) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152634-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS KCNA3, KCNJ1, KCNJ11 ALDH1A1 1621/4885SMN1; SMN2 3669/4885LMNA 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.